NCT01044810 is a clinical trial of Efavirenz-based regimens in Treatment Failure, HIV or AIDS, sponsored by Bamrasnaradura Infectious Diseases Institute.

Who is sponsoring NCT01044810?

NCT01044810 is sponsored by Bamrasnaradura Infectious Diseases Institute.

What drugs are being tested in NCT01044810?

Interventions in NCT01044810: Efavirenz-based regimens.

What condition does NCT01044810 study?

NCT01044810 studies Treatment Failure, HIV or AIDS, CD4 Cell Counts.

Is NCT01044810 still recruiting?

NCT01044810 is currently completed. Last updated 14 March 2011.

Last reviewed 2011-03-14 · How we verify

NCT01044810

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Comparison of Virological and Immunological Results of Efavirenz-based Regimen in HIV-infected Patients With or Without Allergic Reactions to Nevirapine

Completed Last updated 14 March 2011

What this trial tests

trial testing Efavirenz-based regimens in Treatment Failure, HIV or AIDS in 559 participants. Completed in 1 March 2010.

Timeline

1 January 2010

Primary endpoint
1 March 2010

1 March 2010

Quick facts

Lead sponsor	Bamrasnaradura Infectious Diseases Institute
Status	Completed
Study type	OBSERVATIONAL
Enrollment	559
Start date	1 January 2010
Primary completion	1 March 2010
Estimated completion	1 March 2010
Sites	1 location across Thailand

Drugs / interventions tested

Efavirenz-based regimens — full drug profile →

Conditions studied

Treatment Failure, HIV or AIDS — all drugs for Treatment Failure, HIV or AIDS →
CD4 Cell Counts — all drugs for CD4 Cell Counts →

Sponsor

Bamrasnaradura Infectious Diseases Institute

Who can join

Adults 18 to 70, any sex, with Treatment Failure, HIV or AIDS or CD4 Cell Counts. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Time to Virological failure
Time frame: until end of study cohort
Virological failure was defined as either (1) two consecutive results of plasma HIV-1 RNA \>400 copies/ml or (2) plasma HIV-1 RNA \>1,000 copies/ml with genotypic resistance assay revealed NRTI or NNRTI resistance-associated mutations

Sponsor's own description

The primary objective of this study is to compare the effectiveness of EFV-based regimens in HIV-1-infected patients who; (1) were previously allergic to NVP and stopped all ARV simultaneously; (2) were previously allergic to NVP and continued the other NRTIs for a period of time, i.e. "staggered interruption"; and (3) started EFV-based regimens as an initial regimen (as controlled group).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Efavirenz-based regimens

Trials testing the same drug.

NCT01837277 — Impact of a Dolutegravir-based Regimen on Early Mortality of AIDS Patients · Phase 2, PHASE3 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01044810 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bamrasnaradura Infectious Diseases Institute
Last refreshed: 14 March 2011

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01044810.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing